- SMC Ltd. has announced the expansion of its sterile fill finish capabilities. The expansion is taking place in North Carolina.
SMC Ltd. the contract manufacturer exclusively focused on finished medical devices, has announced a major expansion of its sterile fill finish capabilities. The expansion is set to take place in North Carolina. The new facility allows SMC Ltd. to provide a broader range of services to its pharmaceutical clients. These services include developing products from the lab to the market, analysing products, manufacturing devices, filling and finishing products, assembling the final product, and packaging.
VP and General Manager, Uri Baruch commented, “There are notable developments in the injectables market – the growth of more complex biologics and the increased interest in delivering large volumes of API. We believe our ability to deliver, at speed, fill volumes from 1ml to 50ml is an unmet need and is already attracting significant attention from our clients and partners.”
“SMC is recognised globally for its ability to deliver complex, complete drug delivery systems with unrivalled speed and agility. This acquisition not only adds to this capability, it reaffirms our commitment to the pharma market and completes another phase of our growth agenda.”
“At SMC, we have a proud 36-year history of innovating for contract manufacturing and pharma services customers,” said Chetan Patel, SMC Ltd.’s CEO. “This new North Carolina facility is another example of SMC adding the expertise, capabilities, and capacity our customers need to be successful. We know North Carolina’s fill finish capabilities will allow SMC and our pharmaceutical customers to form deeper partnerships well into the future.”
Overview of outsourcing trends 
